TKD Solutions: Expert CGT Problem Solvers

🔬 Turning R&D Into Real-World Impact Andrew Cinderella, Manager of Process R&D at Purisys, is dedicated to solving the challenges that stand between lab discoveries and scalable pharma solutions. His expertise highlights how process innovation and R&D discipline lay the foundation for therapies that actually reach patients. ✨ Pharma Now brings you these exclusive perspectives — the stories behind the science at ChemOutsourcing 2025. 📍 Sept 2–5, 2025 | Parsippany, NJ ChemOutsourcing #PharmaNow #ChemOutsourcing #ProcessDevelopment #PharmaInnovation

MSCs continue to outpace other cell types in therapeutic potential, but successful production depends on optimizing conditions that reflect their in vivo environment. Corning’s experts share workflows, technologies, and case studies to help accelerate MSC-based drug development. 👉 Download the white paper: https://lnkd.in/eaJ7-HZX #MSCs #CellTherapyDevelopment #Bioprocessing #HealthcareInnovation

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/BcgJ30sPi5W #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/VFJr30sPeb2 #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/2Kwi30sPmfr #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/OMXE30sPe2g #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/I3oS30sPcTf #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/PM1I30sPcWR #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/f0K330sPe0E #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading

Weekend reading 📖Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates. Tackling the complexities of bringing novel bioconjugates to the clinic? Our new white paper addresses the critical process development and manufacturing challenges that impede progress. Learn how we help you de-risk, streamline, and accelerate your programs, enabling you to bring transformative therapies to market more efficiently. https://ow.ly/UjPz50WNxKS #Bioconjugates #DrugDevelopment #Biopharma #WeekendReading